As filed with the Securities and Exchange Commission on July 22, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Artiva Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 83-3614316 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| |
5505 Morehouse Drive, Suite 100 San Diego, CA | | 92121 |
(Address of Principal Executive Offices) | | (Zip Code) |
Artiva Biotherapeutics, Inc. 2020 Equity Incentive Plan
Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan
Artiva Biotherapeutics, Inc. 2024 Employee Stock Purchase Plan
(Full titles of the plans)
Fred Aslan, M.D.
President and Chief Executive Officer
Artiva Biotherapeutics, Inc.
5505 Morehouse Drive, Suite 100
San Diego, CA 92121
(858) 267-4467
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Carlos Ramirez
Charles S. Kim
Cooley LLP
10265 Science Center Drive
San Diego, CA 92121
(858) 550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large Accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐